125 related articles for article (PubMed ID: 38692174)
1. MCT4 knockdown by tumor microenvironment-responsive nanoparticles remodels the cytokine profile and eradicates aggressive breast cancer cells.
Abdellatif AAH; Bouazzaoui A; Tawfeek HM; Younis MA
Colloids Surf B Biointerfaces; 2024 Jun; 238():113930. PubMed ID: 38692174
[TBL] [Abstract][Full Text] [Related]
2. Functional screening identifies MCT4 as a key regulator of breast cancer cell metabolism and survival.
Baenke F; Dubuis S; Brault C; Weigelt B; Dankworth B; Griffiths B; Jiang M; Mackay A; Saunders B; Spencer-Dene B; Ros S; Stamp G; Reis-Filho JS; Howell M; Zamboni N; Schulze A
J Pathol; 2015 Oct; 237(2):152-65. PubMed ID: 25965974
[TBL] [Abstract][Full Text] [Related]
3. Roles of acid-extruding ion transporters in regulation of breast cancer cell growth in a 3-dimensional microenvironment.
Andersen AP; Flinck M; Oernbo EK; Pedersen NB; Viuff BM; Pedersen SF
Mol Cancer; 2016 Jun; 15(1):45. PubMed ID: 27266704
[TBL] [Abstract][Full Text] [Related]
4. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231.
Gallagher SM; Castorino JJ; Wang D; Philp NJ
Cancer Res; 2007 May; 67(9):4182-9. PubMed ID: 17483329
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of MCT4 for lactate exchange promotes the cytotoxicity of NK cells in breast carcinoma.
Long Y; Gao Z; Hu X; Xiang F; Wu Z; Zhang J; Han X; Yin L; Qin J; Lan L; Yin F; Wang Y
Cancer Med; 2018 Sep; 7(9):4690-4700. PubMed ID: 30051648
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of monocarboxylate transporter-4 depletes stem-like glioblastoma cells and inhibits HIF transcriptional response in a lactate-independent manner.
Lim KS; Lim KJ; Price AC; Orr BA; Eberhart CG; Bar EE
Oncogene; 2014 Aug; 33(35):4433-41. PubMed ID: 24077291
[TBL] [Abstract][Full Text] [Related]
7. Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer.
Todenhöfer T; Seiler R; Stewart C; Moskalev I; Gao J; Ladhar S; Kamjabi A; Al Nakouzi N; Hayashi T; Choi S; Wang Y; Frees S; Daugaard M; Oo HZ; Fisel P; Schwab M; Schaeffeler E; Douglas J; Hennenlotter J; Bedke J; Gibb EA; Fazli L; Stenzl A; Black PC
Mol Cancer Ther; 2018 Dec; 17(12):2746-2755. PubMed ID: 30262589
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Analysis of Monocarboxylate Transporter 4 (MCT4) expression in breast cancer prognosis and immune infiltration via integrated bioinformatics analysis.
Yuan C; Zhang J; Lou J; Wang S; Jiang Y; Wu F; Wang S
Bioengineered; 2021 Dec; 12(1):3850-3863. PubMed ID: 34269158
[TBL] [Abstract][Full Text] [Related]
9. Monocarboxylate transporter 4, associated with the acidification of synovial fluid, is a novel therapeutic target for inflammatory arthritis.
Fujii W; Kawahito Y; Nagahara H; Kukida Y; Seno T; Yamamoto A; Kohno M; Oda R; Taniguchi D; Fujiwara H; Ejima A; Kishida T; Mazda O; Ashihara E
Arthritis Rheumatol; 2015 Nov; 67(11):2888-96. PubMed ID: 26213210
[TBL] [Abstract][Full Text] [Related]
10. MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis.
Lee JY; Lee I; Chang WJ; Ahn SM; Lim SH; Kim HS; Yoo KH; Jung KS; Song HN; Cho JH; Kim SY; Kim KM; Lee S; Kim ST; Park SH; Lee J; Park JO; Park YS; Lim HY; Kang WK
Oncotarget; 2016 Jul; 7(28):43492-43503. PubMed ID: 27224918
[TBL] [Abstract][Full Text] [Related]
11. Targeting lactate transport suppresses in vivo breast tumour growth.
Morais-Santos F; Granja S; Miranda-Gonçalves V; Moreira AH; Queirós S; Vilaça JL; Schmitt FC; Longatto-Filho A; Paredes J; Baltazar F; Pinheiro C
Oncotarget; 2015 Aug; 6(22):19177-89. PubMed ID: 26203664
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological Inhibition of MCT4 Reduces 4-Hydroxytamoxifen Sensitivity by Increasing HIF-1α Protein Expression in ER-Positive MCF-7 Breast Cancer Cells.
Nadai T; Narumi K; Furugen A; Saito Y; Iseki K; Kobayashi M
Biol Pharm Bull; 2021; 44(9):1247-1253. PubMed ID: 34471053
[TBL] [Abstract][Full Text] [Related]
13. MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4.
Hong CS; Graham NA; Gu W; Espindola Camacho C; Mah V; Maresh EL; Alavi M; Bagryanova L; Krotee PAL; Gardner BK; Behbahan IS; Horvath S; Chia D; Mellinghoff IK; Hurvitz SA; Dubinett SM; Critchlow SE; Kurdistani SK; Goodglick L; Braas D; Graeber TG; Christofk HR
Cell Rep; 2016 Feb; 14(7):1590-1601. PubMed ID: 26876179
[TBL] [Abstract][Full Text] [Related]
14. Monocarboxylate transporter 4 (MCT4) is a high affinity transporter capable of exporting lactate in high-lactate microenvironments.
Contreras-Baeza Y; Sandoval PY; Alarcón R; Galaz A; Cortés-Molina F; Alegría K; Baeza-Lehnert F; Arce-Molina R; Guequén A; Flores CA; San Martín A; Barros LF
J Biol Chem; 2019 Dec; 294(52):20135-20147. PubMed ID: 31719150
[TBL] [Abstract][Full Text] [Related]
15. ZEB1 induces ROS generation through directly promoting MCT4 transcription to facilitate breast cancer.
Han X; Long Y; Duan X; Liu Z; Hu X; Zhou J; Li N; Wang Y; Qin J
Exp Cell Res; 2022 Mar; 412(2):113044. PubMed ID: 35093305
[TBL] [Abstract][Full Text] [Related]
16. Blocking MCT4 SUMOylation inhibits the growth of breast cancer cells.
Hu X; Liu Z; Duan X; Han X; Yuan M; Liu L; Xia X; Li N; Qin J; Wang Y
Mol Carcinog; 2021 Oct; 60(10):702-714. PubMed ID: 34347919
[TBL] [Abstract][Full Text] [Related]
17. In vivo pH in metabolic-defective Ras-transformed fibroblast tumors: key role of the monocarboxylate transporter, MCT4, for inducing an alkaline intracellular pH.
Chiche J; Le Fur Y; Vilmen C; Frassineti F; Daniel L; Halestrap AP; Cozzone PJ; Pouysségur J; Lutz NW
Int J Cancer; 2012 Apr; 130(7):1511-20. PubMed ID: 21484790
[TBL] [Abstract][Full Text] [Related]
18. MCT4 and CD147 colocalize with MMP14 in invadopodia and support matrix degradation and invasion by breast cancer cells.
Meng S; Sørensen EE; Ponniah M; Thorlacius-Ussing J; Crouigneau R; Larsen T; Borre MT; Willumsen N; Flinck M; Pedersen SF
J Cell Sci; 2024 Apr; 137(8):. PubMed ID: 38661040
[TBL] [Abstract][Full Text] [Related]
19. MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis.
Kim HK; Lee I; Bang H; Kim HC; Lee WY; Yun SH; Lee J; Lee SJ; Park YS; Kim KM; Kang WK
Mol Cancer Ther; 2018 Apr; 17(4):838-848. PubMed ID: 29483215
[TBL] [Abstract][Full Text] [Related]
20. Involvement of Monocarboxylate Transporter 4 Expression in Statin-Induced Cytotoxicity.
Kikutani Y; Kobayashi M; Konishi T; Sasaki S; Narumi K; Furugen A; Takahashi N; Iseki K
J Pharm Sci; 2016 Apr; 105(4):1544-9. PubMed ID: 26935883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
